URMD -- Huge market potential Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Stratajema who wrote (33)	3/16/1997 5:25:00 AM
From: Stratajema	of 369

After a second glance, maybe Rochester Medical's (ROCM) device will prove to have a lower incidence of infection when compared to URMD's device. Here's an excerpt from a press release concerning another product of ROCM. I will research further to see if they plan to make their incontinence device medicated. -David STEWARTVILLE, Minn., Nov 5 (Reuter) - Rochester Medical Corp ROCM.O said it will submit the findings of a clinical trial for its new Antibacterial Foley catheter to the U.S. Food and Drug Administration. The company said it will submit the findings in a 510K device application in the coming months, seeking approval to market the catheter in the United Staters. In a statement issued November 4, Rochester Medical said the Antibacterial Foley catheter was found to have a lower rate of catheter-associated bacterial urinary tract infection than a standard, non-medicated catheter in newly catheterized patients. The clinical trial was conducted over the past year at the University of Wisconsin-Madison, and involved over 400 patients in acute care, intensive care unit, and surgical settings. Reuters Chicago Newsdesk - 312-408-8787

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next